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ProcalcitoninPatients contracting avian inﬂuenza A (H7N9) often develop severe disease. However, information on the contri-
bution of bacterial coinfection to the severity of H7N9 is limited. We retrospectively studied 83 patients with
conﬁrmed H7N9 infection from April 2013 to February 2014. The severity of patients with bacterial coinfection
and markers for early diagnosis of bacterial coinfection in H7N9 were analyzed. We found Staphylococcus aureus
was the most prevalent pathogen. Higher Acute Physiology and Chronic Health Evaluation II score, shock, renal
replacement treatment, mechanical ventilation, and extracorporeal membrane oxygenation treatment were
more frequently observed in patients with bacterial coinfection. Procalcitonin is more sensitive than C-reactive
protein in determining bacterial coinfection in H7N9 patients. In conclusion, H7N9 infection patients with bacte-
rial coinfection had amore severe condition. Elevated procalcitonin is an accuratemarker for diagnosing bacterial
coinfection in H7N9 patients, thus enabling earlier antibiotic therapy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A novel avian-origin inﬂuenza A (H7N9) virus had emerged and
spread among humans in China and led to 435 cases by June 27, 2014,
with a mortality rate as high as 36.7% (WHO, nd). Early reports have
shown that H7N9 infection could cause progressive pneumonia and
multiorgan dysfunction, with 63–76.6% of patients being admitted to
an intensive care unit (ICU) (Gao et al., 2013a; Li et al., 2014). Much
effort has beendevoted to investigate the risk factors for theprogression
and the fatal outcome of the disease. Our early ﬁndings have indicated
the presence of a coexisting medical condition as the only independent
risk factor for acute respiratory distress syndrome (Gao et al., 2013a).
Elevated angiotension II levels are associated with the severity of
H7N9-induced disease and may potentially predict patient mortality
(Huang et al., 2014). However, initial studies of H7N9 inﬂuenza describe
few details of patients with bacterial coinfection and the reasonable
selection of antibiotic therapy.
We conducted a retrospective study that focused on the presence of
bacterial coinfection in conﬁrmed cases of H7N9 infection.We aimed to
investigate the incidence of bacterial coinfection, the most common
pathogen, and an accurate diagnosis marker before obtaining positive
cultures for this potential fatal disease and to determine which patients
should receive antibiotic therapy at the time of admission.. This is an open access article under2. Methods
2.1. Study design and patients
We performed a retrospective review of medical records of all
patients with laboratory-conﬁrmed avian H7N9 inﬂuenza infection
(by polymerase chain reaction of nasopharyngeal secretions or bron-
choalveolar lavage ﬂuid) in a large tertiary hospital, the First Afﬁliated
Hospital, School of Medicine, Zhejiang University, China, from April
2013 to February 2014. The following datawere recorded retrospectively:
demographic details, microbiologic ﬁndings, comorbidities, severity of
illness score, the presence of shock, clinical laboratory ﬁndings within
24 h of admission, and outcome on hospital day 90. The need for me-
chanical ventilation, renal replacement therapies, and extracorporeal
membrane oxygenation (ECMO) treatment was also recorded. The
study was approved by the Ethical Board of the First Afﬁliated Hospital,
School of Medicine, Zhejiang University. Written informed consent was
obtained from all patients.
2.2. Deﬁnitions
A conﬁrmed casewas deﬁned as a positive test result for avianH7N9
using reverse transcriptase polymerase chain reaction, as described
previously (Gao et al., 2013b). Bacterial coinfection was deﬁned as any
bacterial infection presumed by the expert group according to clinical
manifestations, with one or more positive cultures or with positivethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Demographic and clinical characteristics of 83 avian H7N9 patients with andwithout bac-
terial coinfection.
Characteristics Bacterial coinfection
(n = 16)
H7N9 only
(n = 67)
P value
Age (years), mean 58.25 ± 17.14 57.58 ± 14.07 0.871
Sex (male), n (%) 8 (50.0%) 47 (70.1%) 0.126
Comorbidities 9 (56.2%) 39 (58.2%) 0.973
Laboratory ﬁnding at admission
Serum creatinine (μmol/L) 110.44 ± 91.11 78.99 ± 67.35 0.122
Serum CK (U/L) 463.81 ± 513.88 403.06 ± 775.13 0.768
Serum LDH (U/L) 783.19 ± 584.47 498.13 ± 300.27 0.007
CRP (mg/dL) 144.82 ± 84.66 85.10 ± 70.01 0.004
PCT (ng/mL) 18.80 ± 28.97 0.58 ± 1.18 0.000
D-Dimer (μg/L) 11914.44 ± 9789.27 5030.78 ± 5527.12 0.000
Leukocyte count (109/L) 6.96 ± 4.43 4.77 ± 3.52 0.037
Platelets counts (109/L) 127.5 ± 82.55 136.07 ± 69.23 0.669
APACHE II score at admission 25.63 ± 5.30 18.57 ± 8.27 0.002
Renal replacement 13 (81.2%) 16 (23.9%) 0.000
Mechanical ventilation 15 (93.8%) 29 (43.3%) 0.000
Shock 10 (62.5%) 19 (28.4%) 0.010
ECMO treatment 8 (50.0%) 14 (20.9%) 0.018
Hospital stay (days), mean 29.88 ± 23.13 24.21 ± 19.77 0.322
30-day mortality, n (%) 7 (43.8%) 11 (16.4%) 0.017
90-day mortality, n (%) 10 (62.5%) 16 (23.9%) 0.003
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detection. The cultures should have been obtained from blood, valid
sputum, lower respiratory tract (endotracheal or bronchoalveolar
lavage) samples, or other normally sterile ﬂuids within the ﬁrst 72 h
of hospitalization. Meanwhile, the urine samples subjected to urine an-
tigen detection should have been positive within 24 h after admission.
To determine the severity of illness, Acute Physiology and Chronic
Health Evaluation (APACHE) II score (Knaus et al., 1985) was calculated
for all patients within 24 h of admission. Shock was deﬁned as that
being treated with vasopressors. Mortality was deﬁned as death occur-
ring anytime after admission and up to day 90.
2.3. Method for procalcitonin (PCT) and C-reactive protein
(CRP) measurement
PCT was tested using the electrochemical luminescence method
(Elecsys Brahms PCT, Mannheim, Germany). CRP was measured using
immunoturbidimetric assays (Beckman, Carlsbad, CA 92010, USA).
2.4. Statistical analyses
Categorical variables are expressed in percentages and frequencies.
Continuous variables are expressedmeans andSD ormedian. Categorical
variables were compared using the chi-square test. Continuous variables
were compared using independent-samples t-test or Mann–Whitney
U test. Univariate and multivariate logistic regression analyses were
performed to predict 90-day mortality. The variables analyzed were
age; gender; comorbidities; presence of shock; APACHE II score; serum
creatinine; serum creatinine kinase (CK); serum lactate dehydrogenase
(LDH); CRP, leukocyte count, platelet count; D-dimer; PCT; bacterial
coinfection; and need for mechanical ventilation, renal replacement,
and ECMO. The diagnostic accuracy of biomarkers (CRP and PCT)
for predicting bacterial coinfection was examined by their receiver
operating characteristic curve (ROC), and the area under the curve
(AUC), sensitivity, and speciﬁcity were also calculated. All tests were 2
tailed, and the signiﬁcance was set at 5%. Data analysis was performed
using SPSS for Windows, version 18.0.
3. Results
During the study period, 83 consecutive patients with laboratory-
conﬁrmed avian H7N9 inﬂuenza infection who were admitted to the
infectious disease department in our hospital were analyzed. The
mean age was 57.71 years (57.71 ± 14.60, range, 21–86 years);
41 (49.4%) patients were older than 60 years, and 55 (66.3%) were
males. Forty-eight patients (57.8%) had comorbidities, of which hyper-
tension and diabetes were the most common. Two (2.4%) patients
were pregnant. The mean APACHE II score at admission was 19.93 ±
8.25. The main demographic and clinical characteristics of patients
with and without bacterial coinfection are detailed in Table 1.
In our study, 16 (19.3%) patients were diagnosed with bacterial
coinfection in the ﬁrst 72 h of admission based on clinical manifesta-
tions, cultures, and urinary antigen detection. However, urine samples
of all patients were negative for S. pneumoniae and L. pneumophila
antigens. The pathogens that caused bacterial coinfections were
Staphylococcus aureus in 4 cases (25%), 3 of which involve methicillin-
resistant S. aureus (MRSA); Staphylococcus hominis in 3 cases; Staphylo-
coccus epidermidis in 2 cases; Ralstonia mannitolilytica in 2 cases;
Acinetobacter baumannii in 2 cases; Pseudomonas aeruginosa in 1 case;
Escherichia coli in 1 case; and Burkholderia cepacia in 1 case. Eight
patients with bacterial coinfection had bacteremia (S. hominis in
3 cases, S. epidermidis in 2 cases, MRSA in 2 cases, and A. baumannii in
1 case). Three patients (3.6%) had both positive respiratory tract
cultures and bacteremia (MRSA in 2 cases and A. baumannii in 1 case).
Patients with bacterial coinfection had a more severe condition than
those without coinfection and had higher APACHE II score (25.63 ±5.30 versus 18.57 ± 8.27, P = 0.000) and were more likely to present
with shock (62.5% versus 28.4%, P = 0.010); were more likely to need
renal replacement treatment (81.2% versus 23.9%, P=0.000),mechanical
ventilation (93.8% versus 43.3%, P=0.000), and ECMO treatment (50.0%
versus 20.9%, P = 0.018); had higher serum levels of LDH, CRP, PCT,
D-dimer, and leukocyte counts; and showed higher 90-day hospital
mortality (62.5% versus 23.9%, P = 0.003). However, there was no
signiﬁcant trend for longer hospital stay. No differences in age,
gender, comorbidities, serum creatinine, CK, and platelets counts
were observed (Table 1).
PCT and CRP levels were obtained, respectively, in 53 and 83 of the
total 83 patients, and 53 patients had both biomarkers measured simul-
taneously within 24 h after admission. Fig. 1 demonstrates the scatter
plot of PCT and CRP values in the 2 groups on admission. Using ROC
analysis, AUC to diagnose bacterial coinfection was 0.96 (95% conﬁ-
dence interval [CI]: 0.91–1.00) for PCT compared with 0.68 (95% CI:
0.50–0.87) for CRP (P = 0.005) (Fig. 2). For PCT at a cutoff value of
0.81 μg/L for diagnosis of bacterial coinfection, the sensitivity was
91.7%, and the speciﬁcity was 90.2%.
All patients received antiviral therapy in our study. Themedian time
from the onset of illness to the initiation of antiviral therapy was 7 days
(range, 1–20); 9.6% (8/83) of the patients received antiviral therapy
within 48 h after the onset of symptoms. The antiviral regimes include
oseltamivir at a daily dose of 150–300 mg in 43 patients, oseltamivir
combined with peramivir at a daily dose of 600 mg in 39 patients, and
peramivir alone in 1 patient.
The mean time from onset to admission was 6.67 (range, 1–15) days.
About 91.2% of our patients had received antibiotics before admission,
and empiric antibiotic therapy was administered to 58 (69.9%) patients
after admission. The antibiotic regimens were beta-lactammonotherapy
(in 41 patients, 69.5%), beta-lactam plus vancomycin (in 6 patients,
10.1%), ﬂuoroquinolone monotherapy (in 4 patients, 6.8%), carbapenem
monotherapy (in 2 patients, 3.4%), vancomycin monotherapy (in 1 pa-
tient, 1.8%), ﬂuoroquinolones plus beta-lactam (in 2 patients, 3.4%), and
fosfomycin monotherapy and other combinations (in 2 patients, 3.4%).
Empiric antibiotic treatment was inappropriate in 4 (25%) of 16 cases
with bacterial coinfection, and 3 patients with inappropriate treatment
died. The pathogens associated with inappropriate treatment were
A. baumannii in 2 cases, 1 case each of MRSA and E. coli.
The all-cause hospital mortality was 28.9% (24/83), and the 90-day
mortality was 31.3% (26/83). In the univariate analysis, age; bacterial
coinfection; comorbidities; APACHE II score; the presence of shock;
Fig. 1. a, PCT values on admission; b, CRP values on admission.
Table 2
Signiﬁcant univariate and multivariate logistic regression analyses of 90-day mortality.
Variable Univariate Multivariate
OR 95% CI P value OR 95% CI P value
Age 1.047 1.008–1.087 0.017 1.057 0.959–1.165 0.265
Bacterial coinfection 0.188 0.059–0.599 0.005 0.284 0.038–2.128 0.221
Comorbidities 0.270 0.094–0.772 0.015 0.251 0.028–2.223 0.214
APACHE II score 1.209 1.107–1.321 0.000 1.135 0.952–1.353 0.158
Shock 0.306 0.116–0.808 0.017 3.618 0.504–25.958 0.201
Renal replacement 0.141 0.050–0.395 0.000 0.217 0.040–1.182 0.077
ECMO 0.248 0.089–0.695 0.008 0.220 0.026–1.876 0.166
CRP 1.009 1.002–1.015 0.010 1.003 0.992–1.014 0.568
D-Dimer 1.000 1.000–1.000 0.001 1.000 1.000–1.000 0.658
Serum LDH 1.003 1.001–1.005 0.004 1.004 1.000–1.008 0.079
Serum CK 1.001 1.000–1.002 0.039 1.001 1.000–1.002 0.054
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levels of CRP, D-dimer, serum LDH, and serum CK were signiﬁcantly
associated with 90-day mortality. However, in multivariate logisticFig. 2. ROC analysis of PCT (solid line) and CRP (dashed line) for predicting bacterial
coinfection at admission, in patients in whom measurements of the 2 biomarkers were
obtained simultaneously (n = 53).regression analysis, the above variables including bacterial coinfection
were not associated with increased mortality (Table 2).4. Discussion
In this study, bacterial coinfection diagnosed within 72 h of admis-
sion was observed in 19.3% of patients with H7N9, and it was also asso-
ciated with the severity of the disease. Increased PCT at a cutoff value of
0.81 μg/L can help identify bacterial coinfection in H7N9 inﬂuenza
patients, thus enabling earlier antibiotic therapy. Although associated
with severity and more treatment intensity, bacterial coinfection was
not the independent predictor of 90-day mortality in these patients.
This is the ﬁrst report on bacterial coinfection in H7N9 inﬂuenza
patients. The rate of bacterial coinfection in pH1N1 infection patients
showed a great variability in different studies, ranging from 17.5% to
51% in critically ill ICU patients (Cilloniz et al., 2012; Estenssoro et al.,
2010; Martin-Loeches et al., 2011; Nguyen et al., 2012; Rice et al.,
2012) and from 25% to 55% in fatal cases with autopsy (Anon, 2009;
Gill et al., 2010; Mauad et al., 2010). In 2 studies that used a similar
deﬁnition of bacterial coinfection in pH1N1 infection patients, Rice
et al. (2012) reported a rate of 30.3%, which included any adult patient
with presumed bacterial pneumonia even if cultures were negative
within 72 h of ICU admission. The study byNguyen et al. (2012) showed
a rate as high as 51% in critically ill children based on positive cultures
within 72 h of admission.
In our study, S. aureuswas the most frequently isolated bacteria. Of
these isolations, 75% were MRSA. One of them with MRSA bacteremia
did not receive appropriate empiric therapy and did not survived.
S. aureus pneumonia is a well-recognized complication of inﬂuenza.
Coinfection with S. aureus, especially with MRSA, has been associated
with severe disease and high mortality rate in adults and children
infected with season inﬂuenza and pH1N1 (Finelli et al., 2008; Kallen
et al., 2009; Nguyen et al., 2012). Clinicians managing patients with
H7N9 inﬂuenza infection should be alert to the possibility of coinfection
with S. aureus.
The cases of infection by coagulase-negative Staphylococcus, such as
S. hominis or S. epidermidis, were considered true infections according to
their clinical manifestations and laboratory ﬁndings for the following
reasons. The novel H7N9 virus causes infection of acute onset and
rapid progression. Up to 64% of the patients in our study were admitted
to the ICU. Most of the patients with 1 or more blood cultures positive
for coagulase-negative Staphylococcus underwent invasive procedures,
such as various forms of intubation, before or immediately after admis-
sion. The coagulase-negative Staphylococcus is a common pathogen in
catheter-related bloodstream infections. Thus, we surmise that these
cultures highly likely represented true, hospital-acquired infections. In
addition to S. aureus, S. pneumoniae was a frequent bacterial pathogen
identiﬁed in patients with pH1N1 infection. Unexpectedly, we did not
168 M. Yang et al. / Diagnostic Microbiology and Infectious Disease 84 (2016) 165–169identify S. pneumoniae or other common bacteria such as Haemophilus
inﬂuenzae and Streptococcus pyogenes in the cultures. About 91.2% of
our patients had received antibiotics before admission to our hospital,
thus possibly limiting the chances of detecting bacterial coinfection
based on a culture test. Thus, the rate of bacterial coinfection in our
series could possibly be underestimated.
Because bacterial coinfection cannot be easily differentiated from
viral infection alone on the basis of the patients' clinical manifestations,
radiological results, and routine laboratory results, 71.2% patients
received antibiotic therapy within 24 h after admission in the initial
111 cases of H7N9 infection (Gao et al., 2013a), even though bacterial
coinfection is considered unlikely. PCT is considered to be a biomarker
for bacterial infection in patients with community-acquired pneumonia
(CAP) andmight be a prognosticmarker in thosewith lower respiratory
tract infections (Gilbert, 2011). Some studies have reported that PCT
levels can help discriminate isolated viral pneumonia from bacterial-
and viral-mixed pneumonia in patients during the 2009 A/H1N1
inﬂuenza pandemic (Cuquemelle et al., 2011; Ingramet al., 2010; Pﬁster
et al., 2014). In our study, we found PCT levels are more sensitive than
CRP levels in discriminating bacterial coinfection in our patients. The
optimal cutoff value of PCT for bacterial coinfection was 0.81 μg/L
(91.7% sensitivity, 90.2% speciﬁcity), with an AUC of 0.96 (0.91–1.00),
which was similar to that previously reported for pH1N1 (Cuquemelle
et al., 2011; Ingram et al., 2010; Pﬁster et al., 2014).
The all-cause hospital mortality of H7N9 cases in our population was
28.9%, which was higher than that due to seasonal inﬂuenza-associated
pneumonia (4.4%) (von Baum et al., 2011) and CAP (4.5%) (Chalmers
et al., 2011) and that previously reported for adult pH1N1 patients
(4.9–23%) (Helferty et al., 2010; Kumar et al., 2009; Rice et al., 2012;
Webbet al., 2009; Zhanget al., 2013) butwas lower than thatdue tohighly
pathogenic avian inﬂuenza A (H5N1) viruses (59%) (Patel et al., 2014).
Although bacterial coinfection was associated with more severe
illness (higher APACHE II score and higher presence of shock); treat-
ment intensity such as a more frequent need for renal replacement
treatment, mechanical ventilation, and ECMO treatment; and 90-day
mortality in the univariate analysis, it was not associated with an
increased mortality in multivariate logistic regression analysis for the
90-day mortality.
Several potential limitations in our study need to be addressed. First,
this was a retrospective and observational study at a single center, and
all patients included in our study were adults. Hence, our results
might not be extended to other countries or to children. Second, we
deﬁned bacterial coinfection as 1 or more positive cultures obtained
from valid samples within the ﬁrst 72 h of hospitalization. We could
not discriminate between community-originated and hospital-
acquired infections. Third, a major limitation is that there is no gold
standard for the deﬁnition of bacterial coinfection in inﬂuenza patients.
So, the “true” proportion of patients with bacterial coinfection is also
difﬁcult to ascertain accurately. Thus, it might decrease the accuracy
of bacterial coinfection rate in H7N9 infection patients, with PCT as a
predictive marker.5. Conclusion
H7N9 infection patientswith bacterial coinfection had amore severe
condition. Elevated PCT is an accurate marker for diagnosis of bacterial
coinfection in inﬂuenza A (H7N9) patients. PCT levels higher than
0.81 μg/L strongly suggest bacterial coinfection in H7N9 inﬂuenza
patients. We suggest that empiric antibiotic therapy should be given
to patients who have bacterial coinfection manifestations and with
PCT levels more than 0.81 μg/L. Furthermore, S. aureus, as well as
MRSA, should be considered in choosing empiric antibiotic therapy
alongside local epidemiological characteristics and drug resistance
trends. Further prospective and intervention studies on bacterial coin-
fection with large sample numbers are needed to clarify the incidence,risk factors, predictor, and preventive and therapy measures in patients
with avian H7N9 virus infection.
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